Myasthenia gravis — autoantibody characteristics and their implications for therapy

@article{Gilhus2016MyastheniaG,
  title={Myasthenia gravis — autoantibody characteristics and their implications for therapy},
  author={Nils Erik Gilhus and Geir Skeie and Fredrik Robert Romi and Konstantinos Lazaridis and Paraskevi Zisimopoulou and Socrates J Tzartos},
  journal={Nature Reviews Neurology},
  year={2016},
  volume={12},
  pages={259-268}
}
Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies that target the neuromuscular junction, leading to muscle weakness and fatigability. Currently available treatments for the disease include symptomatic pharmacological treatment, immunomodulatory drugs, plasma exchange, thymectomy and supportive therapies. Different autoantibody patterns and clinical manifestations characterize different subgroups of the disease: early-onset MG, late-onset MG, thymoma MG, muscle-specific… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 26 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Myasthenia gravis: recent advances in immunopathology and therapy.

Expert review of neurotherapeutics • 2017
View 10 Excerpts
Highly Influenced

Comparative study of video-assisted thoracoscopic surgery versus open thymectomy for thymoma and myasthenia gravis

Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques • 2018

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 78 references

Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis

Cruz, R P.M.
JAMA Neurol • 2015

MuSK frizzled-like domain is critical for mammalian neuromuscular junction formation and maintenance.

The Journal of neuroscience : the official journal of the Society for Neuroscience • 2015

a multinational study

Tsonis, A. I. et al. MuSK autoantibodies in myasthenia gravis assay
J. Neuroimmunol. 284, 10–17 • 2015

a potential target for autoantibodies in myasthenia gravis

Zoltowska, Q K.M.etal.Collagen
J. Neurol. Sci. 348, 241–244 • 2015

a systematic review and metaanalysis

Iorio, R. et al. Efficacy, safety of rituximab for myasthenia gravis
J. Neurol. 262, 1115–1119 • 2015

subgroup classification and therapeutic strategies

N. E. Gilhus, Verschuuren, J. J. Myasthenia gravis
Lancet Neurol. 14, 1023–1036 • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…